Triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the treatment of essential hypertension


Background: Triple drug therapy comprising angiotensin receptor blocker (ARB), calcium channel blocker (CCB) and hydrochlorothiazide (HCT) effectively controls essential hypertension as evident from the literature. This study was undertaken to assess the efficacy and safety of triple combination compared to the dual drug therapy. Methodologies: A total of 220 male and female patients with essential hypertension were enrolled in the study. The patients were divided into two groups. Group A received a bilayer tablet of FDC of Telmisartan + Amlodipine + HCT and group B received FDC tablet of Telmisartan + HCT. Both the treatments were administered once daily for twelve weeks. The patients were asked to follow-up on week 1, 2, 4, 6, 8 and 10 for periodic efficacy and safety evaluations. Effect on systolic blood pressure (SBP), diastolic blood pressure (DBP) and quality of life (QOL) were recorded during the course of the trial. Results: Blood pressure reduction (BP) to the desired goals was observed with both the treatments. The SBP and DBP reductions were superior in triple combination therapy than double combination. Both treatments improved QOL of patients. Conclusion: Triple drug combination of telmisartan, amlodipine and HCT may serve a potential role in achieving desired BP goals, in patients with essential hypertension, which are otherwise poorly managed by either monotherapy or dual drug therapy.

Share and Cite:

Maladkar, M. , Verma, V. , Narsikar, K. , Walinjkar, R. , Patil, W. , Saggu, N. and Kulkarni, S. (2012) Triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the treatment of essential hypertension. Open Journal of Internal Medicine, 2, 67-71. doi: 10.4236/ojim.2012.22014.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Pimenta, E. and Oparil, S. (2008) Fixed combinations in the management of hypertension: Patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vascular Health Risk Management, 4, 653-664.
[2] Swift, P.A. and MacGregor, G.A. (2002) The frequent need for three or more drugs to treat essential hypertension. What evidence for optimal combinations? Journal of Renin-Angiotensin-Aldosterone System, 3, 103-108. doi:10.3317/jraas.2002.010
[3] Plosker, G.L. and White, W.B. (2008) Telmisartan/Hydro chlorothiazide: A review of its use as fixed-dose combinations in essential hypertension. Drugs, 68, 1877-1899. doi:10.2165/00003495-200868130-00010
[4] Lacourcière, Y., Neutel, J.M. and Schumacher, H. (2005) Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clinical Therapeutics, 27, 1795-1805. doi:10.1016/j.clinthera.2005.11.014
[5] Oparil, S., Melino, M., Lee, J., Fernandez, V. and Heyrman, R. (2010) Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clinical Therapeutics, 32, 1252-1269. doi:10.1016/j.clinthera.2010.07.008
[6] Ram, C.V., Sachson, R., Littlejohn, T., Qian, C., Shojaee, A., Stoakes, K.A. and Neutel, J.M. (2011) Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. American Journal of Cardiology, 107, 1346-1352. doi:10.1016/j.amjcard.2010.12.045
[7] Khan, A.H. and Imig, J.D. (2011) Telmisartan provides better renal protection than Valsartan in a rat model of metabolic syndrome. American Journal of Hypertension, 24, 816-821.
[8] Sukumaran, V., Watanabe, K., Veeraveedu, P.T., Ma, M., Gurusamy, N., Rajavel, V., Suzuki, K., Yamaguchi, K., Kodama, M. and Aizawa, Y. (2011) Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress. European Journal of Pharmacology, 652, 126-135.
[9] Maejima, Y., Okada, H., Haraguchi, G., Onai, Y., Kosuge, H., Suzuki, J.-I. and Isobe, M. (2011) Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Laboratory Investigation, 91, 932-944. doi:10.1038/labinvest.2011.45
[10] Inoue, T., Taguchi, I., Abe, S., Toyoda, S., Sakuma, M. and Node, K. (2011) Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan. Journal Clinical Pharmacy & Therapeutics, 36, 103-110. doi:10.1111/j.1365-2710.2010.01161.x
[11] Oigman, W., Neves, M.F. and Gismondi, R.A. (2010) Combination of telmisartan plus amlodipine in the treatment of hypertension: Review of results. Expert Review of Cardiovascular Therapy, 8, 1509-1517. doi:10.1586/erc.10.143
[12] White, W.B., Littlejohn, T.W., Majul, C.R., Oigman, W., Olvera, R., Seeber, M., Schumacher, H. and Mancia, G. (2010) Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Pressure Monitoring, 15, 205-212. doi:10.1097/MBP.0b013e32833c5722
[13] Lacourcière, Y. and Martin, K. (2002) Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. American Journal of Therapeutics, 9, 111-117. doi:10.1097/00045391-200203000-00005
[14] Lacourcière, Y. (2002) A new fixed-dose combination for added blood pressure control: Telmisartan plus hydrochlorothiazide. The Journal of International Medical Research, 30, 366-379.
[15] White, W., Punzi, H., Neutel, J., Davidai, G., Koval, S. and Murwin, D. (2005) Telmisartan plus hydrochlorothiazide (80/25 mg) has a greater antihypertensive effect than valsartan plus hydrochlorothiazide (160/25 mg) in patients with stage 1 and 2 hypertension. American Journal of Hypertension, 18, 97A. doi:10.1016/j.amjhyper.2005.03.271
[16] Mason, R.P. (2002) Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: Review of the evidence. Atherosclerosis, 165, 191. doi:10.1016/S0021-9150(01)00729-8
[17] De Portu, S. and Mantovani, L.G. (2009) Amlodipine: A pharmacoeconomic review. Journal of Medical Economics, 12, 60-68. doi:10.3111/13696990802525266
[18] Nakazato, T., Kawada, T., Shigematsu, T. and Yamada, K. (2002) Left ventricular hypertrophy was infrequent in patients starting dialysis after undergoing a strict blood pressure control in the pre-dialytic period. Internal Medicine, 41, 925-930. doi:10.2169/internalmedicine.41.925
[19] Rakugi, H., Ogihara, T., Goto, Y. and Ishii, M. (2010) Comparison of strict- and mild-blood pressure control in elderly hypertensive patients: A per-protocol analysis of JATOS. Hypertension Research, 33, 1124-1128. doi:10.1038/hr.2010.144
[20] Sato, A., Watanabe, S., Okubo, S., Toi, T., Nakano, H., Tada, J., Aonuma, K. (2010) The therapeutic importance of home blood pressure assessment and combination antihypertensive therapy for achieving target blood pressure control: Ibaraki hypertension assessment trial. Hypertension Research, 33, 1264-1271. doi:10.1038/hr.2010.175
[21] Galzerano, D., Capogrosso, C., Michele, S.D., Galzerano, A., Paparello, P., Lama, D. and Gaudio, C. (2010) new standards in hypertension and cardiovascular risk management: Focus on Telmisartan. Vascular Health and Risk Management, 6, 113-133. doi:10.2147/VHRM.S7857
[22] Fogari, R., Zoppi, A., Mugellini, A., Preti, P., Destro, M., Rinaldi, A. and Derosa, G. (2008) Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: A prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. Current Therapeutic Research, 69, 1-15. doi:10.1016/j.curtheres.2008.02.003
[23] Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jr, Jones, D.W., et al. (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. Journal of American Medical Association, 21, 2560-2572. doi:10.1001/jama.289.19.2560
[24] Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., et al. (2007) Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 28, 1462-1536.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.